Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The population that will be included in this study, will be regular Turkish hypertensive
patients who are expected to consume sodium in high amounts. It is hypothesized that, in that
population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP)
control rate as expected from literature.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Amlodipine Amlodipine, Valsartan Drug Combination Valsartan